Moderna, Merck Melanoma Vaccine May Help Reduce Recurrence, Spread
A personalized mRNA melanoma vaccine developed by Moderna and Merck shows promise in reducing recurrence and spread. Iparraguirre Recio · Moment/Getty
A late-stage trial found that a personalized mRNA therapy for melanoma outperformed Keytruda alone on two important measures